HST Global, Inc. is an integrated health and wellness biotechnology company. The Company is focused on developing and /or acquiring a network of wellness centers worldwide that is primarily focused on the homeopathic and alternative treatment of late-stage cancer. The Company intends to acquire innovative products for the treatment of life-threatening diseases. The Company primarily focuses on homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late-stage cancer and/or life-threatening diseases. It is also focused on funding and developing cutting-edge software solutions. The Company has not generated any revenue.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	140M 123M 114M 105M 197M 13.45B 200M 1.35B 529M 6.61B 524M 513M 22.87B	P/E 2023	-21.8x	P/E 2024	-176x
Enterprise Value	140M 123M 115M 105M 198M 13.51B 201M 1.36B 532M 6.64B 527M 515M 22.96B	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	55.48%	Yield 2023 *	-	Yield 2024	-

11-03	HST Global, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
11-02	HST Global, Inc. Auditor Raises 'Going Concern' Doubt	CI
25-03-19	HST Global, Inc. completed the acquisition of Qwyit LLC from Michael P. Fortkort and R. Paul McGough.	CI
24-11-22	HST Global, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-11-11	HST Global, Inc. acquired Amnion LLC for $2.4 million.	CI
24-08-26	HST Global, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-06-05	HST Global, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24-05-03	Hst Global, Inc. Accepts Resignation of Ron Howell as Director	CI
24-04-05	HST Global, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-04-04	HST Global, Inc. Auditor Raises 'Going Concern' Doubt	CI
23-11-07	HST Global, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
23-08-11	HST Global, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
23-05-12	HST Global, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

24-11-22	HST Global : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)	PU
24-09-26	HST Global : Material Agreement Form 8 K	PU
22-11-04	HST GLOBAL, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
22-07-26	HST GLOBAL, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
22-04-29	HST GLOBAL, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ

Manager	Title	Age	Since
Michael Fortkort CEO	Chief Executive Officer	-	2025-10-06
Mike Field DFI	Director of Finance/CFO	57	2024-04-25

Director	Title	Age	Since
Mike Field BRD	Director/Board Member	57	2024-04-25
Michael Fortkort BRD	Director/Board Member	-	2025-10-06

HST Global, Inc. Stock Other OTC

Stocks

HSTC

US40432E2028

Biotechnology & Medical Research

Valuation: HST Global, Inc.

Latest news : HST Global, Inc.

Analysts' recommendations: HST Global, Inc.

Press Releases: HST Global, Inc.

Quotes and Performance

Managers and Directors: HST Global, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HST GLOBAL, INC.	-52.00%	-.--%	-	-	99M
LONZA GROUP AG	+1.07%	-3.49%	-3.35%	+10.44%	46.86B
REVOLUTION MEDICINES, INC.	+0.25%	+1.65%	+399.22%	+634.87%	40.23B
BEONE MEDICINES AG	-0.27%	+4.45%	+11.81%	+65.64%	36.23B
IQVIA HOLDINGS INC.	+0.35%	+0.87%	+4.46%	-10.16%	34.72B
CELLTRION, INC.	+3.14%	+1.02%	+3.37%	+38.15%	27.89B
MEDPACE HOLDINGS, INC.	-0.73%	+11.84%	+34.39%	+134.36%	16.79B
ASCENDIS PHARMA A/S	+0.47%	-2.74%	-	-	16.74B
EUROFINS SCIENTIFIC SE	+0.42%	-5.52%	-3.43%	+9.03%	13.12B
ICON PUBLIC LIMITED COMPANY	-2.68%	-2.49%	-11.36%	-33.61%	12.7B
Average	-5.00%	+0.83%	+54.39%	+106.09%	27.25B
Weighted average by Cap.	+0.46%	+0.91%	+74.25%	+135.94%

	2023	2024
Net sales	-	-
Net income	-146K -128K -119K -110K -206K -14.08M -209K -1.42M -554K -6.92M -549K -537K -23.93M	-213K -187K -174K -159K -299K -20.48M -304K -2.06M -806K -10.07M -798K -781K -34.81M
Net Debt	96.79K 85.01K 79.06K 72.55K 136K 9.32M 138K 939K 367K 4.58M 363K 356K 15.84M	580K 510K 474K 435K 818K 55.9M 830K 5.63M 2.2M 27.48M 2.18M 2.13M 95.03M